Ze-yang Ding

Hubei Key Laboratory Of Hepato Pancreatic Biliary Diseases
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Interplay among oncogenic pathways governs hepatobiliary lineage decisions in liver cancer.

Interplay among oncogenic pathways governs hepatobiliary lineage decisions in liver cancer.

Journal: iLIVER

Published: February 05, 2026

Mechano-reprogramming of tumor-associated macrophages by engineering nanogel stiffness for suppression of tumor development.

Mechano-reprogramming of tumor-associated macrophages by engineering nanogel stiffness for suppression of tumor development.

Journal: Journal of nanobiotechnology

Published: January 17, 2026

Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets.

Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: July 16, 2025

Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma.

Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma.

Journal: Nature communications

Published: March 08, 2025

Cancer stem cells and niches: challenges in immunotherapy resistance.

Cancer stem cells and niches: challenges in immunotherapy resistance.

Journal: Molecular cancer

Published: December 25, 2024

Regulator of nonsense transcripts 3B is a prognostic biomarker and associated with immune cell infiltration in lung squamous cell and hepatocellular carcinoma.

Regulator of nonsense transcripts 3B is a prognostic biomarker and associated with immune cell infiltration in lung squamous cell and hepatocellular carcinoma.

Journal: Discover oncology

Published: June 21, 2024

Identification of hypermethylated CpG sites mapped to LIFR as specific diagnostic biomarkers of colon cancer.

Identification of hypermethylated CpG sites mapped to LIFR as specific diagnostic biomarkers of colon cancer.

Journal: Genes & diseases

Published: December 02, 2023

Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.

Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.

Journal: Gut

Published: October 18, 2023

Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody followed by simultaneous transcatheter arterial chemoembolization, and portal vein embolization.

Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody followed by simultaneous transcatheter arterial chemoembolization, and portal vein embolization.

Journal: Frontiers in immunology

Published: August 29, 2023

Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies.

Case Report: Durable complete response of metastatic hepatocellular carcinoma with asymptomatic hyperamylasemia to combined immunotherapy of anti-cytotoxic T lymphocyte-associated antigen 4 plus anti-programmed cell death-1 antibodies.

Journal: Frontiers in immunology

Published: August 08, 2023

TGF-β downstream of Smad3 and MAPK signaling antagonistically regulate the viability and partial epithelial-mesenchymal transition of liver progenitor cells.

TGF-β downstream of Smad3 and MAPK signaling antagonistically regulate the viability and partial epithelial-mesenchymal transition of liver progenitor cells.

Journal: Aging

Published: May 12, 2023

GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers.

GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers.

Journal: Cancer gene therapy

Published: March 25, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026